MedCodeSearch
HCPCS Level II Current in October 2026

G0429

Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy)

Release
October 2026
Effective
Official source (opens in a new tab)

Version History

How G0429 appears in each release imported from the official files, newest first.

  1. October 2026 Effective

    Current

    Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy)

  2. July 2026 Effective

    Unchanged

    Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy)

  3. April 2026 Effective

    Unchanged

    Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy)

  4. January 2026 Effective

    Unchanged

    Dermal filler injection(s) for the treatment of facial lipodystrophy syndrome (lds) (e.g., as a result of highly active antiretroviral therapy)

Data Source

Code information on this page is derived from the October 2026 HCPCS Level II files published by CMS.

Release
October 2026
Effective
Source file
october-2026-alpha-numeric-hcpcs-file.zip

Official HCPCS Level II source files (opens in a new tab)

MedCodeSearch is an independent reference service and is not affiliated with CMS, CDC, or the U.S. government.

Look up another code

Search ICD-10-CM, ICD-10-PCS and HCPCS Level II by code or description.